Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Defactinib hydrochloride

🥰Excellent
Catalog No. T15092Cas No. 1073160-26-5
Alias VS-6063 hydrochloride, PF 04554878 hydrochloride

Defactinib hydrochloride (PF 04554878 hydrochloride) is a novel inhibitor of FAK. Which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.

Defactinib hydrochloride

Defactinib hydrochloride

🥰Excellent
Purity: 98.06%
Catalog No. T15092Alias VS-6063 hydrochloride, PF 04554878 hydrochlorideCas No. 1073160-26-5
Defactinib hydrochloride (PF 04554878 hydrochloride) is a novel inhibitor of FAK. Which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.
Pack SizePriceAvailabilityQuantity
2 mg$43In Stock
5 mg$67In Stock
10 mg$96In Stock
25 mg$156In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Defactinib hydrochloride"

Select Batch
Purity:98.06%
Contact us for more batch information
Resource Download
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

Product Introduction

Bioactivity
Description
Defactinib hydrochloride (PF 04554878 hydrochloride) is a novel inhibitor of FAK. Which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.
In vitro
Defactinib suppresses pFAK (protein Focal Adhesion Kinase) expression within three hours, exhibiting a dose-dependent inhibition, particularly at the Tyr397 phosphorylation site, and showing a reduction in expression levels by 48 hours. It effectively diminishes FAK phosphorylation over time and in correlation with the administered dose. Additionally, Reverse Phase Protein Array (RPPA) analysis reveals that Defactinib lowers AKT and YB-1 levels in taxane-resistant cell lines. The inhibition of pFAK (Tyr397) by Defactinib is confirmed to be statistically significant and dose-responsive across various cell lines, as documented in source [1].
In vivo
In the HeyA8 model, PTX monotherapy achieved an 87.4% decrease in tumor weight, while combination therapy yielded a superior 97.9% reduction (P=0.05 compared with PTX). Defactinib treatment at 25 mg/kg, administered orally twice daily, significantly decreased pFAK (Tyr397) levels, with effects reversing within 24 hours, establishing this dose for further experiments. For these, female nude mice with HeyA8 tumors in the peritoneal cavity were divided into four groups (n=10 each): 1) control group receiving vehicle and phosphate-buffered saline, 2) Defactinib (25 mg/kg orally, twice daily), 3) PTX weekly, and 4) both Defactinib and PTX. The SKOV3ip1 model demonstrated a 92.7% tumor weight reduction with the combination therapy compared to PTX alone (P<0.001)[1].
AliasVS-6063 hydrochloride, PF 04554878 hydrochloride
Chemical Properties
Molecular Weight546.95
FormulaC20H22ClF3N8O3S
Cas No.1073160-26-5
SmilesCl.CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(C)(=O)=O)n2)C(F)(F)F)cc1
Relative Density.no data available
Storage & Solubility Information
Storagekeep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 22.5 mg/mL (41.1 mM), Sonication is recommended.
H2O: 0.1 mg/mL (insoluble)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.8283 mL9.1416 mL18.2832 mL91.4160 mL
5 mM0.3657 mL1.8283 mL3.6566 mL18.2832 mL
10 mM0.1828 mL0.9142 mL1.8283 mL9.1416 mL
20 mM0.0914 mL0.4571 mL0.9142 mL4.5708 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Defactinib hydrochloride | purchase Defactinib hydrochloride | Defactinib hydrochloride cost | order Defactinib hydrochloride | Defactinib hydrochloride chemical structure | Defactinib hydrochloride in vivo | Defactinib hydrochloride in vitro | Defactinib hydrochloride formula | Defactinib hydrochloride molecular weight